Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.53 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769940 | 0.90 | HTR4 (0.52) | SMYD3CACNA1IKCNH2HTR4MCHR1 | |
| SCHEMBL16459248 | 0.88 | SMYD3 (0.49) | SMYD3CACNA1IKCNH2HTR4MCHR1 | |
| SCHEMBL4271194 | 0.82 | KCNH2 (0.48) | SMYD3CACNA1IKCNH2HTR4 | |
| SCHEMBL19113011 | 0.75 | KMT2A (0.66) | CACNA1IKCNH2HTR4BCHEMAOB | |
| SCHEMBL19113201 | 0.74 | CACNA1I (0.56) | CACNA1IKCNH2HTR4 | |
| SCHEMBL19113036 | 0.74 | CACNA1I (0.56) | CACNA1IKCNH2HTR4HDAC3HDAC4 | |
| SCHEMBL4278328 | 0.74 | KDM4E (0.43) | SMYD3CACNA1IKCNH2HTR4MCHR1 | |
| SCHEMBL1427922 | 0.73 | KCNH2 (0.76) | CACNA1IKCNH2MCHR1 | |
| SCHEMBL19113186 | 0.73 | CHRM2 (0.55) | CACNA1IKCNH2HTR4HDAC3HDAC4 | |
| SCHEMBL19113599 | 0.72 | CACNA1I (0.53) | CACNA1IKCNH2HTR4BCHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | SMYD3 3801/4885CACNA1I 4/4885KCNH2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.